What is Baxter International?

What is Baxter International?

Baxter International is a public hospital products and infusion systems company headquartered in Deerfield, IL. Baxter's 2025 continuing-operations sales were about $11.3 billion after the Kidney Care separation, with Q4 2025 sales from continuing operations of $2.97 billion.

Baxter International operates in hospital products and infusion systems with a portfolio that includes Infusion systems, IV solutions, Nutrition therapies, Advanced surgery products. Baxter's 2025 continuing-operations sales were about $11.3 billion after the Kidney Care separation, with Q4 2025 sales from continuing operations of $2.97 billion. The company employs about 37,500+ and trades as NYSE: BAX, so its buying motion looks like a regulated enterprise account rather than a startup account.

Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Baxter International through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.

For sellers, Baxter International is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.

Sources:Baxter International 2025 resultsBaxter International annual reports

What does Baxter International offer?

Baxter International offers products and services across Infusion systems, IV solutions, Nutrition therapies, Advanced surgery products and related healthcare workflows.

Sources:Baxter International websiteBaxter International annual reports

How does Baxter International make money?

Baxter International earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.

Baxter International earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $11.3B 2025 continuing operations of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.

Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.

Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Baxter International improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.

Sources:Baxter International 2025 resultsBaxter International annual reports

Who leads Baxter International?

Baxter International is led by Andrew Hider, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.

Sources:Baxter International leadershipBaxter International annual reports

How do you contact Baxter International's leadership?

Baxter International publishes official Baxter investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.

• Andrew HiderPresident and Chief Executive Officerofficial Baxter investor-relations contact route
• Joel GradeExecutive Vice President and Chief Financial Officerofficial Baxter investor-relations contact route
• Heather KnightExecutive Vice President and Chief Operating Officerofficial Baxter investor-relations contact route

Sources:Baxter International contactBaxter International leadership

How much funding has Baxter International raised?

Baxter International is a mature public company, not a venture-backed startup. It trades as NYSE: BAX and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.

Baxter International's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.

As of June 2026, the current capital lens is NYSE: BAX, $11.3B 2025 continuing operations of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.

Seller signal: Baxter International has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.

Sources:Baxter International 2025 resultsNYSE: BAX market data

How did Baxter International get here?

Baxter International grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.

Sources:Baxter International annual reportsBaxter International 2025 results

Who are Baxter International's competitors?

Baxter International competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.

Sources:Baxter International annual reportsBaxter International website